Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
GSTT1 null (OR 0.50, 95 % CI 0.31-0.81; P = 0.005) and GSTP1 Val105Val (OR 0.52, 95 % CI 0.27-0.98; P = 0.04) genotypes were associated with reduced BC risk separately or in combination (OR 0.24, 95 % CI 0.11-0.51; P < 0.0001) (P heterogeneity = 0.01).
|
24919441 |
2014 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings support the role for the GSTM1 null and the GSTP1 313 AG or GG genotypes in the development of bladder cancer.
|
11757669 |
2001 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
GSTP1 Ile(105)Val variants (deletion of one - Ile/Val- and two -Val/Val-, null genotype- copies) showed a marginal increased risk of BC with OR adjusted for smoking status of 2.27 (95% CI, 0.97-5.31) compared to individuals carrying wild-type genotype (Ile/Ile).
|
19443378 |
2009 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, no associations were observed between GSTA1 or GSTP1 polymorphisms and BCa susceptibility.
|
27631264 |
2016 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thus, it is evident from our study that GSTP1 SNP is not implicated overall in bladder cancer, but that the rare, valine-related allele is connected with higher susceptibility to bladder cancer in smokers and also males.
|
24377535 |
2013 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis shows that there is an obvious association between GSTP1 Ile105ValIle105Val polymorphism and bladder cancer risk, and GSTP1 ILE105VAL polymorphism contributes to bladder cancer risk.
|
23483487 |
2013 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Data indicated that in Caucasians exposed to aromatic amines the GSTP1 A1578G polymorphism did not appear to play a significant role as a predisposing factor for bladder cancer incidence.
|
18569592 |
2008 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that GSTP1 313 G/G polymorphism is a strong predisposing risk factor for BC.
|
23054023 |
2013 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These data seem to indicate that the GSTP1 GG genotype is associated with a modest increase in the risk of bladder cancer in a Chinese population.
|
21117956 |
2011 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
GSTM1, GSTT1 and GSTP1 genotype frequencies were determined in bladder cancer cases (n=72) and healthy controls with no history of malignancies (n=82) using PCR-based techniques.
|
15832776 |
2005 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
No differences for GSTM1 and GSTP1 genotype prevalence between the bladder cancer cases and the controls were observed, however, the null genotype for the GSTT1 gene and the A/G and G/G variants of the CYP1A1 gene may contribute to the development of bladder cancer.
|
18979064 |
2009 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Glutathione S-Transferase Pi 1 (GSTP1) Gene rs1695" genes_norm="2950">313 A/G (rs1695) polymorphism is associated with the risk of urinary bladder cancer: Evidence from a systematic review and meta-analysis based on 34 case-control studies.
|
31454540 |
2019 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Previous studies have associated polymorphisms of GSTA1, GSTM1, and GSTP1 genes with a higher risk of bladder cancer, but this is still controversial.
|
24075358 |
2013 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
GSTP1 Ile 105Val appears to be associated with a modest increase in the risk of bladder cancer.
|
17404387 |
2007 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The results of our study demonstrated that the GSTP1 313 G/G polymorphism is a strong predisposing risk factor for bladder cancer in the North Indian population.
|
15780023 |
2005 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
No association was found between the genetic polymorphisms investigated and BC risk according to coffee consumption apart of a significant increased BC risk among GSTP1 105-114 Val carriers heavy coffee drinkers (>3 cups/day) (OR 3.18, 95% CI 1.06-9.55).
|
18365755 |
2008 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
An overrepresentation of GSTP1 AG or GG genotype corresponding a less stable and less effective isozyme protein was detected in patients with benzidine related occupational bladder cancer, compared with that in the normal population though a statistical significance was not yet reached (P = 0.09, OR = 1.96, 95% CI 0.89-4.32).
|
12500666 |
2002 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
There was a significant multiple interaction between GSTM1, GSTT1, and GSTP1 genotypes in risk of bladder cancer (P for interaction = 0.02).
|
22154357 |
2013 |
Malignant neoplasm of urinary bladder
|
0.600 |
Biomarker
|
disease |
CTD_human |
A case-control study of polymorphisms in xenobiotic and arsenic metabolism genes and arsenic-related bladder cancer in New Hampshire.
|
22306368 |
2012 |
Malignant neoplasm of urinary bladder
|
0.600 |
Biomarker
|
disease |
CTD_human |
An overrepresentation of GSTP1 AG or GG genotype corresponding a less stable and less effective isozyme protein was detected in patients with benzidine related occupational bladder cancer, compared with that in the normal population though a statistical significance was not yet reached (P = 0.09, OR = 1.96, 95% CI 0.89-4.32).
|
12500666 |
2002 |
Malignant neoplasm of urinary bladder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Individual null/low-activity genotypes of GSTM1, GSTT1 and GSTP1 were associated with a 19-48% increase in odds ratio (OR) of bladder cancer.
|
18544563 |
2008 |
Malignant neoplasm of urinary bladder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our data suggest that tumor suppressive miR-133a directly regulated oncogenic GSTP1 gene in BC, and that an anti-apoptotic effect mediated by GSTP1 is maintained by miR-133a down-regulation in human BC.
|
21396852 |
2013 |
Malignant neoplasm of urinary bladder
|
0.600 |
Biomarker
|
disease |
BEFREE |
GSTM(my)1 has been associated with an increased risk of colorectal cancer, lung cancer, and bladder cancer and GSTP(pi)1 with prostate cancer.
|
16399374 |
2005 |
Malignant neoplasm of urinary bladder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genotyping of GSTM1 and GSTP1 in bladder cancer patients was assessed using polymerase chain reaction followed by DNA sequencing.
|
31646988 |
2019 |
Malignant neoplasm of urinary bladder
|
0.600 |
Biomarker
|
disease |
BEFREE |
An increased but not significant frequency of GSTP1 AG or GG carriers was observed in the occupationally exposed bladder cancer patient group [odds ratio (OR)=1.95, 95% confidence interval (CI) 0.70-5.46].
|
12835616 |
2003 |